IMMUNOHISTOCHEMICAL ANALYSIS OF P53 PROTEIN OVEREXPRESSION IN LIVER-CELL DYSPLASIA AND IN HEPATOCELLULAR-CARCINOMA

被引:44
作者
ZHAO, M
ZHANG, NX
LAISSUE, JA
ZIMMERMANN, A
机构
[1] UNIV BERN,INST PATHOL,CH-3010 BERN,SWITZERLAND
[2] TIANJIN MED COLL,DEPT PATHOL,TIANJIN,PEOPLES R CHINA
来源
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY | 1994年 / 424卷 / 06期
关键词
P53; EXPRESSION; HEPATOCELLULAR CARCINOMA; LIVER CELL DYSPLASIA;
D O I
10.1007/BF01069741
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We analysed p53 protein immunoreactivity in hepatocellular carcinomas (HCCs) and in liver cell dysplasia (LCD) of patients from an area in Northern China, using five anti-p53 protein antibodies recognizing different epitopes of the protein. In HCCs, the overall prevalence of p53 protein immunoreactivity was 78.3%. However, prevalence was strongly influenced by the type of antibody used, ranging from 67.5% for antibody PAb-1801 to only 10.8% for antibodies PAb-421 and DO-7. p53 protein immunoreactivity was not related to type or grade of HCC. In contrast to former reports, p53 protein staining was restricted to nuclei only when using the CM-1 antibody, whereas two other antibodies yielded both, nuclear and cytoplasmic or membrane staining, and no nuclear staining was observed with antibodies PAb-421 and DO-7, the latter two, however, demonstrating cytoplasmic and membrane staining. For LCD, three subtypes were morphologically and karyometrically defined. Nuclei of some LCD cells were p53 immunoreactive, but positivity was restricted to the small cell variant of LCD. Positivity was different for cirrhosis with or without associated HCC, amounting to 18.9% in the former and 39.4% in the latter. Interestingly, p53 protein immunoreactivity also occurred in a set of small hepatocytes not showing the typical features of LCD and therefore classified as simple regenerating liver cells.
引用
收藏
页码:613 / 621
页数:9
相关论文
共 67 条
[1]  
ANTHONY PP, 1976, CANCER RES, V36, P2579
[2]   ISOLATION OF HUMAN-P53-SPECIFIC MONOCLONAL-ANTIBODIES AND THEIR USE IN THE STUDIES OF HUMAN P53 EXPRESSION [J].
BANKS, L ;
MATLASHEWSKI, G ;
CRAWFORD, L .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 159 (03) :529-534
[3]  
BARTEK J, 1991, ONCOGENE, V6, P1699
[4]  
BRAUN L, 1989, CANCER RES, V49, P1554
[5]   SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA [J].
BRESSAC, B ;
KEW, M ;
WANDS, J ;
OZTURK, M .
NATURE, 1991, 350 (6317) :429-431
[6]   LOW-FREQUENCY OF P53 MUTATIONS OBSERVED IN A DIVERSE COLLECTION OF PRIMARY HEPATOCELLULAR CARCINOMAS [J].
BUETOW, KH ;
SHEFFIELD, VC ;
ZHU, MH ;
ZHOU, TL ;
SHEN, FM ;
HINO, O ;
SMITH, M ;
MCMAHON, BJ ;
LANIER, AP ;
LONDON, WT ;
REDEKER, AG ;
GOVINDARAJAN, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (20) :9622-9626
[7]   ANALYSIS OF THE P53 TUMOR-SUPPRESSOR GENE IN HEPATOCELLULAR CARCINOMAS FROM BRITAIN [J].
CHALLEN, C ;
LUNEC, J ;
WARREN, W ;
COLLIER, J ;
BASSENDINE, MF .
HEPATOLOGY, 1992, 16 (06) :1362-1366
[8]  
CHOI SW, 1993, LIVER, V13, P172
[9]  
COLTRERA MD, 1992, AM J PATHOL, V141, P817
[10]  
COLTRERA MD, 1993, APPL IMMUNOHISTO M M, V1, P193